V. Hawkins

发表

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer

G. Sonpavde, J. Levitt, K. Slawin, 2017, Cancer Immunology, Immunotherapy.

Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).

G. Sonpavde, J. Bull, J. Levitt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.